NewsBenzingaGenmab A/S、ペトセムタマブの第3相LiGeR-HN1試験データを発表 ― 頭頸部扁平上皮がん治療において死亡リスクを50%低減することを示す Genmab A/S、ペトセムタマブの第3相LiGeR-HN1試験データを発表 ― 頭頸部扁平上皮がん治療において死亡リスクを50%低減することを示す Benzinga 2026.10.28 13:45 (GMT+0) Open on Benzinga Other news Dan Ives Says ‘Clearly Jensen Wants to Come Back as CEO’, Sees Potential Special Shareholder Meeting Telsey Advisory Group Maintains Market Perform on Kohl's, Raises Price Target to $25 Red Cat Q3 Revenue Contracts 42% in Q3, Analysts Cut Price Targets Citigroup Maintains Neutral on Petrobras Brasileiro, Lowers Price Target to $18.5 Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels Lake Street Maintains Buy on Envela, Lowers Price Target to $16
Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels